79691-19-3

Upstream product

• 79691-14-8 4(R)-(tert-butyldimethylsiloxy)-6(R)-<2-<1,2,6,7,8,8a(S)-hexahydro-8(S)-hydroxy-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-2-<(tetrahydropyran-2-yl)oxy>-3,4,5,6-tetrahydro-2H-pyran 
• 352-11-4 1-chloromethyl-4-fluorobenzene 

Downstream Products

• 79691-21-7 4(R)-(tert-butyldimethylsiloxy)-6(R)-<2-<8(S)-<(4-fluorobenzyl)oxy>-1,2,6,7,8,8a(S)-hexahydro-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 79691-18-2 6(R)-<2-<8(S)-<(4-fluorobenzyl)oxy>-1,2,6,7,8,8a(S)-hexahydro-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 79691-20-6 4(R)-(tert-butyldimethylsiloxy)-6(R)-<2-<8(S)-<(4-fluorobenzyl)oxy>-1,2,6,7,8,8a(S)-hexahydro-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran 

Relevant academic research and scientific papers

3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors. 8. Side Chain Ether Analogues of Lovastatin

A general route for preparing side chain ether analogues of lovastatin is presented.These analogues proved to be weaker inhibitors of HMG-CoA reductase than the corresponding side chain ester analogues.Interestingly, inhibitory potency was enhanced marked